{
    "clinical_study": {
        "@rank": "11494", 
        "acronym": "NEBOSA", 
        "arm_group": [
            {
                "arm_group_label": "Nebivolol  then CPAP", 
                "arm_group_type": "Experimental", 
                "description": "8 weeks of Nebivolol treatment (5m/day), 6 weeks of washout, 8 weeks of CPAP and  if the patient is still hypertensive 8 weeks of Nebivolol plus CPAP treatment"
            }, 
            {
                "arm_group_label": "CPAP then Nebivolol", 
                "arm_group_type": "Experimental", 
                "description": "8 weeks of CPAP treatment, 6 weeks of washout, 8 weeks of Nebivolol and  if the patient is still hypertensive 8 weeks of Nebivolol plus CPAP treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to examine how effective CPAP treatment and treatment with\n      nebivolol are respectively on reducing blood pressure and on endothelial dysfunction in\n      patients suffering from obstructive sleep apnea and hypertension."
        }, 
        "brief_title": "CPAP and Nebivolol in Hypertensive Obstructive Sleep Apnea (OSA) Patients.", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hypertension", 
            "Endothelial Dysfunction", 
            "Obstructive Sleep Apnea"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Apnea", 
                "Hypertension", 
                "Sleep Apnea Syndromes", 
                "Sleep Apnea, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  male/female \u2265 18 years old\n\n          -  patient with obstructive sleep apnea (apnea-hypopnea index \u2265  20) na\u00efve for CPAP\n             treatment\n\n          -  patient with weak or moderate hypertension (140 <=  systolic blood pressure (SBP) <\n             180 mmHg and 90 <= diastolic blood pressure (DBP) < 110 mmHg na\u00efve for any\n             antihypertensive treatment\n\n          -  negative pregnancy test\n\n          -  ambulatory patient\n\n          -  patient who have signed the informed consent form\n\n          -  patient affiliated to social security\n\n        Exclusion Criteria:\n\n          -  pregnant or nursing woman\n\n          -  acute hepatic failure, biliary cirrhosis, cholestasis\n\n          -  clearance of Cockcroft < 30 ml/min/1.73m2\n\n          -  sick sinus syndrome, including sino-atrial block\n\n          -  second and third degree heart block (without a pacemaker)\n\n          -  history of bronchospasm and bronchial asthma\n\n          -  bradycardia (heart rate< 60bpm prior to start therapy)\n\n          -  severe peripheral circulatory disturbances\n\n          -  acute hypertension (SBP>= 180 mmHg and/or DBP >= 110 mmHg)\n\n          -  severe daytime sleepiness (Epworth rating scale > 15)\n\n          -  known cardiovascular pathologies\n\n          -  contraindication to CPAP\n\n          -  allergy to nebivolol\n\n          -  patient treated with antihypertensive drug(s), with class I antiarrhythmics\n             (quinidine, hydroquinidine, cibenzoline, flecainide, disopyramide, lidocaine,\n             mexiletine, propafenone)\n\n          -  patient treated with CPAP\n\n          -  patient kept in detention, major protected by the law, hospitalised person\n\n          -  patient currently participating in another clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01771406", 
            "org_study_id": "S54613"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Nebivolol  then CPAP", 
                    "CPAP then Nebivolol"
                ], 
                "description": "8 weeks of Nebivolol treatment (5mg/day)", 
                "intervention_name": "Nebivolol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Nebivolol  then CPAP", 
                    "CPAP then Nebivolol"
                ], 
                "description": "8 weeks of CPAP treatment", 
                "intervention_name": "Continuous positive airway pressure (CPAP)", 
                "intervention_type": "Device", 
                "other_name": "Philips Respironics Remstar System One"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Nebivolol"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 15, 2013", 
        "location": {
            "contact": {
                "last_name": "Catharina Belge, M.D., Ph.D.", 
                "phone": "+3216342520"
            }, 
            "facility": {
                "address": {
                    "city": "Leuven", 
                    "country": "Belgium", 
                    "zip": "3000"
                }, 
                "name": "University Hospitals Leuven"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Continuous Positive Airway Pressure (CPAP) and Nebivolol Treatment on Arterial Blood Pressure and Endothelial Function in Hypertensive OSA Patients.", 
        "overall_contact": {
            "email": "secretariaat.slaaplabo@uzleuven.be", 
            "last_name": "Catharina Belge, M.D., Ph. D.", 
            "phone": "+3216342520"
        }, 
        "overall_official": {
            "affiliation": "University Hospitals, Leuven", 
            "last_name": "Catharina Belge, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "change in mean arterial blood pressure", 
            "safety_issue": "No", 
            "time_frame": "measurement assessed at w8,w14,w22"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01771406"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "change in endothelial function", 
            "safety_issue": "No", 
            "time_frame": "measurement assessed at w8,w14,w22"
        }, 
        "source": "Universitaire Ziekenhuizen Leuven", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universitaire Ziekenhuizen Leuven", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}